FDA finds no new or unexpected safety risks associated with pimavanserin use in Parkinsons disease psychosis
An analysis of all postmarketing reports of deaths and serious adverse events (SAEs) reported with the use of Nuplazid (pimavanserin) by the US FDA has found no new or unexpected safety risks associated with Nuplazid (pimavanserin), which is used to treat the hallucinations and delusions of Parkinson’s disease psychosis. In a statement issued September 20, 2018, the FDA said, “the drug’s benefits outweigh its risks for patients with hallucinations and delusions of Par
To continue reading this article
Continue reading your article with a eMediNexus account.